Abstract: For pediatric patients with pityriasis rubra pilaris (PRP), mild cases are often treated topically with external medications. For patients with more severe conditions or inadequate response to local therapy, systemic treatments such as retinoids and immunosuppressants like methotrexate may be administered. However, these options are associated with numerous adverse effects, and no definitive treatment efficacy rates have been established. In recent years, there have been reports of biologics and small molecule drugs demonstrating both safety and effectiveness in treating PRP. This article presents a case of a male patient with recurrent juvenile PRP who achieved near-complete resolution of skin lesions after one month of tofacitinib treatment and remained recurrence-free during a three-year follow-up period.

Key words: tofacitinib, pityriasis rubra pilaris, juvenile